---
document_datetime: 2025-12-29 13:33:11
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/vaxchora.html
document_name: vaxchora.html
version: success
processing_time: 0.1283126
conversion_datetime: 2025-12-31 04:05:28.167229
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Vaxchora

[RSS](/en/individual-human-medicine.xml/67294)

##### Authorised

This medicine is authorised for use in the European Union

cholera vaccine, oral, live Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Vaxchora](#news-on)
- [Preventing medication errors](#preventing-medication-errors-1586)
- [More information on Vaxchora](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Vaxchora is a vaccine to prevent cholera disease in adults and children aged from 2 years. Cholera is a disease that is caught from contaminated food or drink and causes severe diarrhoea.

The vaccine contains a weakened form of the cholera bacterium *Vibrio cholerae* (serogroup O1).

Expand section

Collapse section

## How is Vaxchora used?

Vaxchora can only be obtained with a prescription. It should be used according to official recommendations.

The vaccine is made up in water and taken by mouth as a single dose at least 10 days before the person is likely to come into contact with cholera bacteria.

For more information about using Vaxchora, see the package leaflet or contact your doctor or pharmacist.

## How does Vaxchora work?

When a person receives Vaxchora, the immune system (the body's defences) recognises the weakened bacteria in the vaccine as foreign and makes antibodies against them. When the person comes into contact with potentially disease-causing cholera bacteria, the immune system will be ready to produce antibodies and in this way remove the bacteria quickly and so prevent cholera disease.

## What benefits of Vaxchora have been shown in studies?

A main study involving 197 healthy adults aged 18 to 45 years found that Vaxchora can prevent symptoms of cholera in people coming into contact with cholera bacteria.

In this study, individuals received a single dose of either Vaxchora or placebo (a dummy vaccine) and were then given infectious cholera bacteria (O1 strain). Moderate to severe diarrhoea (a symptom of cholera) occurred in about 6% of those given the cholera bacteria 10 days after Vaxchora and 12% of those given the bacteria 3 months after receiving Vaxchora. By comparison, moderate to severe diarrhoea occurred in 59% of adults who had received placebo.

Another main study involving 3,022 healthy adults aged 18 to 45 years found that antibodies against cholera bacteria were present after 11 days in 94% of adults who had received Vaxchora compared with 4% in those who received placebo.

Further studies confirmed that giving Vaxchora to adults aged 46 to 64 years or to children and adolescents aged 2 to 18 years was effective at producing antibodies against cholera bacteria.

## What are the risks associated with Vaxchora?

The most common side effects with Vaxchora (which may affect more than 1 in 10 people) are tiredness, headache, abdominal (belly) pain, feeling sick, vomiting and loss of appetite.

People who were born with problems with their immune system or are receiving treatment that weakens the immune system must not take Vaxchora.

For the full list of restrictions and side effects of Vaxchora, see the package leaflet.

## Why is Vaxchora authorised in the EU?

Vaxchora is effective for protecting vaccinated individuals against moderate and severe cholera disease. Measurement of antibodies after vaccination showed that it is effective in individuals from 2 years of age. The European Medicines Agency noted that evidence from Vaxchora studies is relevant only for travellers visiting areas where cholera is present. It is not known how long the protection lasts. The Agency considered that Vaxchora's side effects are manageable. The Agency therefore decided that Vaxchora's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Vaxchora?

The company that markets Vaxchora will provide a guide for healthcare professionals and a patient guide on how to make up and take the vaccine to avoid medication errors, especially in children aged 2 to 6 years.

Recommendations and precautions to be followed by healthcare professionals and those taking the vaccine for the safe and effective use of Vaxchora have also been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Vaxchora are continuously monitored. Side effects reported with Vaxchora are carefully evaluated and any necessary action taken to protect those taking the vaccine.

## Other information about Vaxchora

Vaxchora received a marketing authorisation valid throughout the EU on 1 April 2020.

Vaxchora : EPAR - Medicine overview

Reference Number: EMA/69968/2021

English (EN) (133.16 KB - PDF)

**First published:** 08/04/2020

**Last updated:** 07/04/2021

[View](/en/documents/overview/vaxchora-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-402)

български (BG) (144.36 KB - PDF)

**First published:**

08/04/2020

**Last updated:**

07/04/2021

[View](/bg/documents/overview/vaxchora-epar-medicine-overview_bg.pdf)

español (ES) (115.31 KB - PDF)

**First published:**

08/04/2020

**Last updated:**

07/04/2021

[View](/es/documents/overview/vaxchora-epar-medicine-overview_es.pdf)

čeština (CS) (143.1 KB - PDF)

**First published:**

08/04/2020

**Last updated:**

07/04/2021

[View](/cs/documents/overview/vaxchora-epar-medicine-overview_cs.pdf)

dansk (DA) (120.14 KB - PDF)

**First published:**

08/04/2020

**Last updated:**

07/04/2021

[View](/da/documents/overview/vaxchora-epar-medicine-overview_da.pdf)

Deutsch (DE) (127.17 KB - PDF)

**First published:**

08/04/2020

**Last updated:**

07/04/2021

[View](/de/documents/overview/vaxchora-epar-medicine-overview_de.pdf)

eesti keel (ET) (118.67 KB - PDF)

**First published:**

08/04/2020

**Last updated:**

07/04/2021

[View](/et/documents/overview/vaxchora-epar-medicine-overview_et.pdf)

ελληνικά (EL) (157.27 KB - PDF)

**First published:**

08/04/2020

**Last updated:**

07/04/2021

[View](/el/documents/overview/vaxchora-epar-medicine-overview_el.pdf)

français (FR) (114.26 KB - PDF)

**First published:**

08/04/2020

**Last updated:**

07/04/2021

[View](/fr/documents/overview/vaxchora-epar-medicine-overview_fr.pdf)

hrvatski (HR) (141.39 KB - PDF)

**First published:**

08/04/2020

**Last updated:**

07/04/2021

[View](/hr/documents/overview/vaxchora-epar-medicine-overview_hr.pdf)

italiano (IT) (119.82 KB - PDF)

**First published:**

08/04/2020

**Last updated:**

07/04/2021

[View](/it/documents/overview/vaxchora-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (151.81 KB - PDF)

**First published:**

08/04/2020

**Last updated:**

07/04/2021

[View](/lv/documents/overview/vaxchora-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (144.15 KB - PDF)

**First published:**

08/04/2020

**Last updated:**

07/04/2021

[View](/lt/documents/overview/vaxchora-epar-medicine-overview_lt.pdf)

magyar (HU) (140.91 KB - PDF)

**First published:**

08/04/2020

**Last updated:**

07/04/2021

[View](/hu/documents/overview/vaxchora-epar-medicine-overview_hu.pdf)

Malti (MT) (151.3 KB - PDF)

**First published:**

08/04/2020

**Last updated:**

07/04/2021

[View](/mt/documents/overview/vaxchora-epar-medicine-overview_mt.pdf)

Nederlands (NL) (121.1 KB - PDF)

**First published:**

08/04/2020

**Last updated:**

07/04/2021

[View](/nl/documents/overview/vaxchora-epar-medicine-overview_nl.pdf)

polski (PL) (148.19 KB - PDF)

**First published:**

08/04/2020

**Last updated:**

07/04/2021

[View](/pl/documents/overview/vaxchora-epar-medicine-overview_pl.pdf)

português (PT) (122.09 KB - PDF)

**First published:**

08/04/2020

**Last updated:**

07/04/2021

[View](/pt/documents/overview/vaxchora-epar-medicine-overview_pt.pdf)

română (RO) (150.23 KB - PDF)

**First published:**

08/04/2020

**Last updated:**

07/04/2021

[View](/ro/documents/overview/vaxchora-epar-medicine-overview_ro.pdf)

slovenčina (SK) (144.39 KB - PDF)

**First published:**

08/04/2020

**Last updated:**

07/04/2021

[View](/sk/documents/overview/vaxchora-epar-medicine-overview_sk.pdf)

slovenščina (SL) (128.49 KB - PDF)

**First published:**

08/04/2020

**Last updated:**

07/04/2021

[View](/sl/documents/overview/vaxchora-epar-medicine-overview_sl.pdf)

Suomi (FI) (120.31 KB - PDF)

**First published:**

08/04/2020

**Last updated:**

07/04/2021

[View](/fi/documents/overview/vaxchora-epar-medicine-overview_fi.pdf)

svenska (SV) (118.58 KB - PDF)

**First published:**

08/04/2020

**Last updated:**

07/04/2021

[View](/sv/documents/overview/vaxchora-epar-medicine-overview_sv.pdf)

Vaxchora : EPAR - Risk-management-plan summary

English (EN) (120.56 KB - PDF)

**First published:** 08/04/2020

**Last updated:** 31/05/2022

[View](/en/documents/rmp-summary/vaxchora-epar-risk-management-plan-summary_en.pdf)

## Product information

Vaxchora : EPAR - Product information

English (EN) (423.04 KB - PDF)

**First published:** 08/04/2020

**Last updated:** 24/09/2025

[View](/en/documents/product-information/vaxchora-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-881)

български (BG) (608.05 KB - PDF)

**First published:**

08/04/2020

**Last updated:**

24/09/2025

[View](/bg/documents/product-information/vaxchora-epar-product-information_bg.pdf)

español (ES) (518.59 KB - PDF)

**First published:**

08/04/2020

**Last updated:**

24/09/2025

[View](/es/documents/product-information/vaxchora-epar-product-information_es.pdf)

čeština (CS) (871.75 KB - PDF)

**First published:**

08/04/2020

**Last updated:**

24/09/2025

[View](/cs/documents/product-information/vaxchora-epar-product-information_cs.pdf)

dansk (DA) (523.08 KB - PDF)

**First published:**

08/04/2020

**Last updated:**

24/09/2025

[View](/da/documents/product-information/vaxchora-epar-product-information_da.pdf)

Deutsch (DE) (515.66 KB - PDF)

**First published:**

08/04/2020

**Last updated:**

24/09/2025

[View](/de/documents/product-information/vaxchora-epar-product-information_de.pdf)

eesti keel (ET) (541.63 KB - PDF)

**First published:**

08/04/2020

**Last updated:**

24/09/2025

[View](/et/documents/product-information/vaxchora-epar-product-information_et.pdf)

ελληνικά (EL) (726.21 KB - PDF)

**First published:**

08/04/2020

**Last updated:**

24/09/2025

[View](/el/documents/product-information/vaxchora-epar-product-information_el.pdf)

français (FR) (855.5 KB - PDF)

**First published:**

08/04/2020

**Last updated:**

24/09/2025

[View](/fr/documents/product-information/vaxchora-epar-product-information_fr.pdf)

hrvatski (HR) (695.4 KB - PDF)

**First published:**

08/04/2020

**Last updated:**

24/09/2025

[View](/hr/documents/product-information/vaxchora-epar-product-information_hr.pdf)

íslenska (IS) (523.16 KB - PDF)

**First published:**

08/04/2020

**Last updated:**

24/09/2025

[View](/is/documents/product-information/vaxchora-epar-product-information_is.pdf)

italiano (IT) (503.83 KB - PDF)

**First published:**

08/04/2020

**Last updated:**

24/09/2025

[View](/it/documents/product-information/vaxchora-epar-product-information_it.pdf)

latviešu valoda (LV) (606.98 KB - PDF)

**First published:**

08/04/2020

**Last updated:**

24/09/2025

[View](/lv/documents/product-information/vaxchora-epar-product-information_lv.pdf)

lietuvių kalba (LT) (507.83 KB - PDF)

**First published:**

08/04/2020

**Last updated:**

24/09/2025

[View](/lt/documents/product-information/vaxchora-epar-product-information_lt.pdf)

magyar (HU) (608.14 KB - PDF)

**First published:**

08/04/2020

**Last updated:**

24/09/2025

[View](/hu/documents/product-information/vaxchora-epar-product-information_hu.pdf)

Malti (MT) (658.54 KB - PDF)

**First published:**

08/04/2020

**Last updated:**

24/09/2025

[View](/mt/documents/product-information/vaxchora-epar-product-information_mt.pdf)

Nederlands (NL) (514.67 KB - PDF)

**First published:**

08/04/2020

**Last updated:**

24/09/2025

[View](/nl/documents/product-information/vaxchora-epar-product-information_nl.pdf)

norsk (NO) (517.65 KB - PDF)

**First published:**

08/04/2020

**Last updated:**

24/09/2025

[View](/no/documents/product-information/vaxchora-epar-product-information_no.pdf)

polski (PL) (625.12 KB - PDF)

**First published:**

08/04/2020

**Last updated:**

24/09/2025

[View](/pl/documents/product-information/vaxchora-epar-product-information_pl.pdf)

português (PT) (518.37 KB - PDF)

**First published:**

08/04/2020

**Last updated:**

24/09/2025

[View](/pt/documents/product-information/vaxchora-epar-product-information_pt.pdf)

română (RO) (600.48 KB - PDF)

**First published:**

08/04/2020

**Last updated:**

24/09/2025

[View](/ro/documents/product-information/vaxchora-epar-product-information_ro.pdf)

slovenčina (SK) (587.21 KB - PDF)

**First published:**

08/04/2020

**Last updated:**

24/09/2025

[View](/sk/documents/product-information/vaxchora-epar-product-information_sk.pdf)

slovenščina (SL) (572.24 KB - PDF)

**First published:**

08/04/2020

**Last updated:**

24/09/2025

[View](/sl/documents/product-information/vaxchora-epar-product-information_sl.pdf)

Suomi (FI) (422.78 KB - PDF)

**First published:**

08/04/2020

**Last updated:**

24/09/2025

[View](/fi/documents/product-information/vaxchora-epar-product-information_fi.pdf)

svenska (SV) (392 KB - PDF)

**First published:**

08/04/2020

**Last updated:**

24/09/2025

[View](/sv/documents/product-information/vaxchora-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000282352 23/09/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Vaxchora : EPAR - All authorised presentations

English (EN) (44.52 KB - PDF)

**First published:** 08/04/2020

**Last updated:** 27/09/2022

[View](/en/documents/all-authorised-presentations/vaxchora-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-610)

български (BG) (95.07 KB - PDF)

**First published:**

08/04/2020

**Last updated:**

27/09/2022

[View](/bg/documents/all-authorised-presentations/vaxchora-epar-all-authorised-presentations_bg.pdf)

español (ES) (46.47 KB - PDF)

**First published:**

08/04/2020

**Last updated:**

27/09/2022

[View](/es/documents/all-authorised-presentations/vaxchora-epar-all-authorised-presentations_es.pdf)

čeština (CS) (79.46 KB - PDF)

**First published:**

08/04/2020

**Last updated:**

27/09/2022

[View](/cs/documents/all-authorised-presentations/vaxchora-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (53.27 KB - PDF)

**First published:**

08/04/2020

**Last updated:**

27/09/2022

[View](/da/documents/all-authorised-presentations/vaxchora-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (82.97 KB - PDF)

**First published:**

08/04/2020

**Last updated:**

27/09/2022

[View](/de/documents/all-authorised-presentations/vaxchora-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (46.56 KB - PDF)

**First published:**

08/04/2020

**Last updated:**

27/09/2022

[View](/et/documents/all-authorised-presentations/vaxchora-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (76.22 KB - PDF)

**First published:**

08/04/2020

**Last updated:**

27/09/2022

[View](/el/documents/all-authorised-presentations/vaxchora-epar-all-authorised-presentations_el.pdf)

français (FR) (66.58 KB - PDF)

**First published:**

08/04/2020

**Last updated:**

27/09/2022

[View](/fr/documents/all-authorised-presentations/vaxchora-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (66.1 KB - PDF)

**First published:**

08/04/2020

**Last updated:**

27/09/2022

[View](/hr/documents/all-authorised-presentations/vaxchora-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (31.14 KB - PDF)

**First published:**

08/04/2020

**Last updated:**

27/09/2022

[View](/is/documents/all-authorised-presentations/vaxchora-epar-all-authorised-presentations_is.pdf)

italiano (IT) (46.23 KB - PDF)

**First published:**

08/04/2020

**Last updated:**

27/09/2022

[View](/it/documents/all-authorised-presentations/vaxchora-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (72.66 KB - PDF)

**First published:**

08/04/2020

**Last updated:**

27/09/2022

[View](/lv/documents/all-authorised-presentations/vaxchora-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (68.92 KB - PDF)

**First published:**

08/04/2020

**Last updated:**

27/09/2022

[View](/lt/documents/all-authorised-presentations/vaxchora-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (52.72 KB - PDF)

**First published:**

08/04/2020

**Last updated:**

27/09/2022

[View](/hu/documents/all-authorised-presentations/vaxchora-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (70.77 KB - PDF)

**First published:**

08/04/2020

**Last updated:**

27/09/2022

[View](/mt/documents/all-authorised-presentations/vaxchora-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (46.04 KB - PDF)

**First published:**

08/04/2020

**Last updated:**

27/09/2022

[View](/nl/documents/all-authorised-presentations/vaxchora-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (32.89 KB - PDF)

**First published:**

08/04/2020

**Last updated:**

27/09/2022

[View](/no/documents/all-authorised-presentations/vaxchora-epar-all-authorised-presentations_no.pdf)

polski (PL) (70.17 KB - PDF)

**First published:**

08/04/2020

**Last updated:**

27/09/2022

[View](/pl/documents/all-authorised-presentations/vaxchora-epar-all-authorised-presentations_pl.pdf)

português (PT) (46.14 KB - PDF)

**First published:**

08/04/2020

**Last updated:**

27/09/2022

[View](/pt/documents/all-authorised-presentations/vaxchora-epar-all-authorised-presentations_pt.pdf)

română (RO) (70.18 KB - PDF)

**First published:**

08/04/2020

**Last updated:**

27/09/2022

[View](/ro/documents/all-authorised-presentations/vaxchora-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (68.72 KB - PDF)

**First published:**

08/04/2020

**Last updated:**

27/09/2022

[View](/sk/documents/all-authorised-presentations/vaxchora-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (52.33 KB - PDF)

**First published:**

08/04/2020

**Last updated:**

27/09/2022

[View](/sl/documents/all-authorised-presentations/vaxchora-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (50.99 KB - PDF)

**First published:**

08/04/2020

**Last updated:**

27/09/2022

[View](/fi/documents/all-authorised-presentations/vaxchora-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (44.53 KB - PDF)

**First published:**

08/04/2020

**Last updated:**

27/09/2022

[View](/sv/documents/all-authorised-presentations/vaxchora-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Vaxchora Active substance vibrio cholerae, strain cvd 103-hgr, live International non-proprietary name (INN) or common name cholera vaccine, oral, live Therapeutic area (MeSH) Cholera Anatomical therapeutic chemical (ATC) code J07AE02

### Pharmacotherapeutic group

Vaccines

### Therapeutic indication

Vaxchora is indicated for active immunisation against disease caused by Vibrio cholerae serogroup O1 in adults and children aged 2 years and older.

This vaccine should be used in accordance with official recommendations.

## Authorisation details

EMA product number EMEA/H/C/003876 Marketing authorisation holder

Bavarian Nordic A/S

Bavarian Nordic A/S

Opinion adopted 30/01/2020 Marketing authorisation issued 01/04/2020 Revision 10

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Vaxchora : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (144.68 KB - PDF)

**First published:** 24/09/2025

[View](/en/documents/procedural-steps-after/vaxchora-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Vaxchora : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (177.74 KB - PDF)

**First published:** 22/06/2020

**Last updated:** 24/09/2025

[View](/en/documents/procedural-steps-after/vaxchora-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Vaxchora-H-C-003876-II-0003-G : EPAR - Assessment report - Variation

Adopted

Reference Number: EMA/CHMP/444278/2020

English (EN) (4.5 MB - PDF)

**First published:** 07/04/2021

[View](/en/documents/variation-report/vaxchora-h-c-003876-ii-0003-g-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Vaxchora (II-03-G)

Adopted

Reference Number: EMA/CHMP/46810/2021

English (EN) (146.95 KB - PDF)

**First published:** 01/02/2021

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-vaxchora-ii-03-g_en.pdf)

## Initial marketing authorisation documents

Vaxchora : EPAR - Public assessment report

Adopted

Reference Number: EMA/82271/2020

English (EN) (2.29 MB - PDF)

**First published:** 08/04/2020

[View](/en/documents/assessment-report/vaxchora-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Vaxchora

Adopted

Reference Number: EMA/CHMP/33389/2020

English (EN) (141.63 KB - PDF)

**First published:** 31/01/2020

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-vaxchora_en.pdf)

#### News on Vaxchora

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-29 January 2021](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-25-29-january-2021) 29/01/2021

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 27-30 January 2020](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-27-30-january-2020) 31/01/2020

#### Preventing medication errors

Vaxchora: avoiding errors when making up and using the vaccine

Adopted

Reference Number: EMA/68844/2020

English (EN) (179.13 KB - PDF)

**First published:** 08/04/2020

[View](/en/documents/medication-error/vaxchora-avoiding-errors-when-making-and-using-vaccine_en.pdf)

[Other languages (22)](#file-language-dropdown-559)

български (BG) (206.84 KB - PDF)

**First published:**

08/04/2020

[View](/bg/documents/medication-error/vaxchora-avoiding-errors-when-making-and-using-vaccine_bg.pdf)

español (ES) (177.68 KB - PDF)

**First published:**

08/04/2020

[View](/es/documents/medication-error/vaxchora-avoiding-errors-when-making-and-using-vaccine_es.pdf)

čeština (CS) (198.23 KB - PDF)

**First published:**

08/04/2020

[View](/cs/documents/medication-error/vaxchora-avoiding-errors-when-making-and-using-vaccine_cs.pdf)

dansk (DA) (178.69 KB - PDF)

**First published:**

08/04/2020

[View](/da/documents/medication-error/vaxchora-avoiding-errors-when-making-and-using-vaccine_da.pdf)

Deutsch (DE) (181.5 KB - PDF)

**First published:**

08/04/2020

[View](/de/documents/medication-error/vaxchora-avoiding-errors-when-making-and-using-vaccine_de.pdf)

eesti keel (ET) (177.01 KB - PDF)

**First published:**

08/04/2020

[View](/et/documents/medication-error/vaxchora-avoiding-errors-when-making-and-using-vaccine_et.pdf)

ελληνικά (EL) (199.1 KB - PDF)

**First published:**

08/04/2020

[View](/el/documents/medication-error/vaxchora-avoiding-errors-when-making-and-using-vaccine_el.pdf)

français (FR) (180.21 KB - PDF)

**First published:**

08/04/2020

[View](/fr/documents/medication-error/vaxchora-avoiding-errors-when-making-and-using-vaccine_fr.pdf)

hrvatski (HR) (194.68 KB - PDF)

**First published:**

08/04/2020

[View](/hr/documents/medication-error/vaxchora-avoiding-errors-when-making-and-using-vaccine_hr.pdf)

italiano (IT) (177.84 KB - PDF)

**First published:**

08/04/2020

[View](/it/documents/medication-error/vaxchora-avoiding-errors-when-making-and-using-vaccine_it.pdf)

latviešu valoda (LV) (206.47 KB - PDF)

**First published:**

08/04/2020

[View](/lv/documents/medication-error/vaxchora-avoiding-errors-when-making-and-using-vaccine_lv.pdf)

lietuvių kalba (LT) (199.65 KB - PDF)

**First published:**

08/04/2020

[View](/lt/documents/medication-error/vaxchora-avoiding-errors-when-making-and-using-vaccine_lt.pdf)

magyar (HU) (199.31 KB - PDF)

**First published:**

08/04/2020

[View](/hu/documents/medication-error/vaxchora-avoiding-errors-when-making-and-using-vaccine_hu.pdf)

Malti (MT) (201.79 KB - PDF)

**First published:**

08/04/2020

[View](/mt/documents/medication-error/vaxchora-avoiding-errors-when-making-and-using-vaccine_mt.pdf)

Nederlands (NL) (177.75 KB - PDF)

**First published:**

08/04/2020

[View](/nl/documents/medication-error/vaxchora-avoiding-errors-when-making-and-using-vaccine_nl.pdf)

polski (PL) (198.32 KB - PDF)

**First published:**

08/04/2020

[View](/pl/documents/medication-error/vaxchora-avoiding-errors-when-making-and-using-vaccine_pl.pdf)

português (PT) (178.29 KB - PDF)

**First published:**

08/04/2020

[View](/pt/documents/medication-error/vaxchora-avoiding-errors-when-making-and-using-vaccine_pt.pdf)

română (RO) (197.99 KB - PDF)

**First published:**

08/04/2020

[View](/ro/documents/medication-error/vaxchora-avoiding-errors-when-making-and-using-vaccine_ro.pdf)

slovenčina (SK) (198.69 KB - PDF)

**First published:**

08/04/2020

[View](/sk/documents/medication-error/vaxchora-avoiding-errors-when-making-and-using-vaccine_sk.pdf)

slovenščina (SL) (194.97 KB - PDF)

**First published:**

08/04/2020

[View](/sl/documents/medication-error/vaxchora-avoiding-errors-when-making-and-using-vaccine_sl.pdf)

Suomi (FI) (177.28 KB - PDF)

**First published:**

08/04/2020

[View](/fi/documents/medication-error/vaxchora-avoiding-errors-when-making-and-using-vaccine_fi.pdf)

svenska (SV) (177.97 KB - PDF)

**First published:**

08/04/2020

[View](/sv/documents/medication-error/vaxchora-avoiding-errors-when-making-and-using-vaccine_sv.pdf)

#### More information on Vaxchora

- [EMEA-001490-PIP01-13-M04 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001490-pip01-13-m04)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)
- [Vaccines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A76)

**This page was last updated on** 24/09/2025

## Share this page

[Back to top](#main-content)